CD47-SIRPalpha Blockade Agent Safety Killing Methods Patent
Summary
The European Patent Office published Sana Biotechnology Inc.'s patent application EP4225332A1 covering methods for triggering safety killing mechanisms using CD47-SIRPalpha blockade agents. The patent relates to cellular therapy applications including allogeneic cell transplants and engineered cell products. The application covers A61K and C07K classification technologies with designated states spanning 31 European countries.
What changed
EPO published European patent application EP4225332A1 for Sana Biotechnology Inc., titled 'METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRP alpha BLOCKADE AGENT.' The application covers therapeutic methods utilizing CD47-SIRPalpha pathway blockade to trigger safety killing mechanisms in cell-based therapies, relevant to allogeneic cell transplants and engineered cellular products.
For biotechnology companies and pharmaceutical developers working on CD47-SIRPaxis targeting therapies or cell therapy products, this patent represents potential blocking intellectual property in European markets. Sana Biotechnology gains priority rights across 31 designated EPC contracting states. Competitors should assess this intellectual property when developing similar therapeutic approaches for commercialization in Europe.
What to do next
- Monitor patent prosecution timeline for EP4225332A1
- Review freedom-to-operate implications if developing CD47-SIRPalpha therapeutics in Europe
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS FOR TRIGGERING SAFETY KILLING MECHANISMS USING A CD47-SIRP alpha BLOCKADE AGENT
Publication EP4225332A1 Kind: A1 Apr 01, 2026
Applicants
Sana Biotechnology, Inc.
Inventors
SCHREPFER, Sonja
IPC Classifications
A61K 35/17 20150101AFI20250306BHEP C07K 14/725 20060101ALI20250306BHEP C12N 5/0783 20100101ALI20250306BHEP A61K 31/513 20060101ALI20250306BHEP A61K 31/522 20060101ALI20250306BHEP A61K 38/20 20060101ALI20250306BHEP A61K 39/395 20060101ALI20250306BHEP A61K 40/11 20250101ALI20250306BHEP A61K 40/15 20250101ALI20250306BHEP A61K 40/17 20250101ALI20250306BHEP A61K 40/24 20250101ALI20250306BHEP A61K 40/31 20250101ALI20250306BHEP A61K 40/42 20250101ALI20250306BHEP A61K 39/00 20060101ALI20250306BHEP C07K 14/705 20060101ALI20250306BHEP C07K 16/28 20060101ALI20250306BHEP C12N 15/86 20060101ALI20250306BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.